CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 4, 2010, Pages 933-943

  Körner, Meike ^a   Waser, Beatrice ^b   Reubi, Jean Claude ^b   Miller, Laurence J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

CCK2 receptor intron 4 splice variant; Gastrointestinal stromal tumour; Receptor autoradiography; RT PCR; Small cell lung cancer

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; GASTROINTESTINAL TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTRON; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD;

ALTERNATIVE SPLICING; AUTORADIOGRAPHY; BINDING SITES; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRONS; LUNG NEOPLASMS; RECEPTOR, CHOLECYSTOKININ B; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 77953938452     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00859.x     Document Type: Article

References (41)

1. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 2001, 63:49-76.
2. Reubi JC. Targeting CCK receptors in human cancers. Curr Top Med Chem 2007, 7:1239-42.
3. Behr TM, Bèhè MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002, 32:97-109.
4. Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol 2002, 91:333-350.
5. Baldwin GS, Shulkes A. CCK receptors and cancer. Curr Top Med Chem 2007, 7:1232-8.
6. Hellmich MR, Rui XL, Hellmich HL. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J Biol Chem 2000, 275:32122-8.
7. Ding WQ, Kuntz SM, Miller LJ. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. Cancer Res 2002, 62:947-52.
8. Cheng ZJ, Harikumar KG, Ding WQ. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett 2005, 222:95-105.
9. Chao C, Tallman ML, Ives KL. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005, 129:313-21.
10. Olszewska-Pazdrak B, Townsend CM, Hellmich MR. Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem 2004, 279:40400-4.
11. Schmitz F, Otte JM, Stechele HU. CCK-B/gastrin receptors in human colorectal cancer. Eur J Clin Invest 2001, 31:812-20.
12. Gales C, Sanchez D, Poirot M. High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene 2003, 22:6081-9.
13. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004, 64:7647-54.
14. Xing Y. Genomic analysis of RNA alternative splicing in cancers. Front Biosci 2007, 12:4034-41.
15. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007, 39:1432-49.
16. Smith JP, Verderame MF, McLaughlin P. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med 2002, 10:689-94.
17. Zhou J, Chen M, Zhang Q. Human gastric tissues simultaneously express the classical and alternative splicing cholecystokinin-B/gastrin receptors. Receptors Channels 2004, 10:185-8.
18. Harris JC, Clarke PA, Awan A. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004, 64:1915-9.
19. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997, 57:1377-86.
20. Reubi JC, Waser B, Schmassmann A. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int J Cancer 1999, 81:376-86.
21. Reubi JC, Zimmermann A, Jonas S. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999, 45:766-74.
22. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003, 30:781-93.
23. Reubi JC, Waser B, Gugger M. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology 2003, 125:98-106.
24. Reubi JC, Körner M, Waser B. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004, 31:803-10.
25. Körner M, Hayes GM, Rehmann R. Secretin receptors in the human liver: Expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol 2006, 45:825-35.
26. Miller JA, Zahniser NR. The use of 14C-labeled tissue paste standards for the calibration of 125I-labeled ligands in quantitative autoradiography. Neurosci Lett 1987, 81:345-50.
27. Baskin DG, Wimpy TH. Calibration of [14C]plastic standards for quantitative autoradiography of [125I]labeled ligands with Amersham Hyperfilm beta-max. Neurosci Lett 1989, 104:171-7.
28. Pfaffl MW. Quantification strategies in real-time PCR. A-Z of quantitative PCR 2004, 87-120. Bustin SA. editor, LaJolla, IUL Biotechnology Series
29. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-93.
30. Schmittgen TD, Teske S, Vessella RL. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003, 107:323-9.
31. Schmitz F, Schrader H, Otte J. Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul Pept 2001, 101:25-33.
32. Galindo J, Jones N, Powell GL. Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas. Pancreas 2005, 31:325-31.
33. Miller LJ, Dong M, Harikumar KG. Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem 2007, 12:1166-72.
34. Chao C, Ives KL, Goluszko E. SRC regulates constitutive internalization and rapid resensitization of a cholecystokinin 2 receptor splice variant. J Biol Chem 2005, 280:33368-73.
35. Chao C, Goluszko E, Lee YT. Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth. Oncogene 2007, 26:1013-9.
36. Cheng ZJ, Harikumar KG, Holicky EL. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem 2003, 278:52972-9.
37. Hayes GM, Carrigan PE, Dong M. A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. Gastroenterology 2007, 133:8-861.
38. Okamoto I, Morisaki T, Sasaki J. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst 1998, 90:307-15.
39. Miyake H, Eto H, Arakawa S. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002, 167:1282-7.
40. Dong WG, Sun XM, Yu BP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 2003, 9:2596-600.
41. Laverman P, Roosenburg S, Gotthardt M. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008, 35:386-92.